Recent News

By Region: North America

U.S. funds multiple vaccine device

(UPI) A $3.5 million grant is being given a U.S. public/private partnership for advancing development of a new device to simultaneously deliver multiple vaccines. Receiving the grant from the National Institute of Allergy and Infectious Diseases is Inovio Pharmaceuticals Inc., which is collaborating with the chief scientist at the U.S. Army Medical Research Institute of Read More »

April 12, 2013
| Filed under North America and Countermeasures
Share

BARDA Public Health and Medical Consequence Modeling Network

(GlobalBiodefense) The Biomedical Advanced Research and Development Agency Division of Analytic Decision Support (BARDA/ADS) is seeking tools to support decision-making against Chemical, Biological, Radiological, and Nuclear (CBRN) threat agents, pandemic influenza, and emerging infectious diseases. The solicitation calls for visual analytics, data informatics, models, and simulation tools to help better inform planners, communicate results to Read More »

April 12, 2013
| Filed under North America and Public Health
Share

Lab Prepares New Bioagent Infection Detector

(GlobalSecurityNewswire) The Sandia National Laboratories in New Mexico is preparing a hand-held device that hospitals could one day use to quickly test patients for infection by anthrax, ricin or other potential bioterror agents. The enhanced version of the SpinDx device would allow emergency room doctors to analyze blood samples to determine within 15 minutes whether Read More »

April 12, 2013
| Filed under North America and Biotechnology
Share

Scientists use nature against nature to develop an antibiotic with reduced resistance

(EurekAlert) A new broad range antibiotic, developed jointly by scientists at The Rockefeller University and Astex Pharmaceuticals, has been found to kill a wide range of bacteria, including drug-resistant Staphylococcus (MRSA) bacteria that do not respond to traditional drugs, in mice. The antibiotic, Epimerox, targets weaknesses in bacteria that have long been exploited by viruses Read More »

April 11, 2013
| Filed under North America and Research
Share

Launch of semi-synthetic artemisinin a milestone for malaria, synthetic biology

(EurekAlert) Twelve years after a breakthrough discovery in his University of California, Berkeley, laboratory, professor of chemical engineering Jay Keasling is seeing his dream come true. On April 11, the pharmaceutical company Sanofi will launch the large-scale production of a partially synthetic version of artemisinin, a chemical critical to making today’s front-line antimalaria drug, based Read More »